Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Payables (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Payables for 16 consecutive years, with $14.4 million as the latest value for Q4 2025.

  • For Q4 2025, Payables fell 6.77% year-over-year to $14.4 million; the TTM value through Dec 2025 reached $14.4 million, down 6.77%, while the annual FY2025 figure was $14.4 million, 6.77% down from the prior year.
  • Payables hit $14.4 million in Q4 2025 for Sangamo Therapeutics, down from $15.6 million in the prior quarter.
  • Across five years, Payables topped out at $22.4 million in Q4 2022 and bottomed at $8.0 million in Q3 2021.
  • Average Payables over 5 years is $14.8 million, with a median of $15.4 million recorded in 2023.
  • Year-over-year, Payables plummeted 55.4% in 2021 and then surged 129.72% in 2022.
  • Sangamo Therapeutics' Payables stood at $9.8 million in 2021, then soared by 129.72% to $22.4 million in 2022, then crashed by 31.93% to $15.3 million in 2023, then increased by 1.48% to $15.5 million in 2024, then fell by 6.77% to $14.4 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $14.4 million, $15.6 million, and $10.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.